Ignite Creation Date:
2024-07-17 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06473493
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-25
First Post:
2024-06-13
Brief Title:
The Safety and Efficacy of Alverine in the Treatment of Cirrhotic Portal Hypertension
Sponsor:
Shanghai Changzheng Hospital
Organization:
Shanghai Changzheng Hospital
Study Overview
Official Title:
The Safety and Efficacy of Compound Alverine Citrate Soft Capsules in the Treatment of Portal Hypertension in Patients With Liver Cirrhosis a Multicentre Single-arm Exploratory Trial s a Multicentre Single-arm Exploratory Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Study Overall Design This trial is a prospective multi-center single-arm exploratory clinical study Subjects who meet the inclusion criteria and do not meet the exclusion criteria will receive Compound Alverine Citrate Capsules Lejiansu specification each capsule contains 60 mg of Alverine Citrate and 300 mg of Simethicone produced by Laboratoires Mayoly Spindler France after signing the informed consent form The dosage is 180 mgday 1 capsule orally three times a day for a treatment period of 24 weeks Apart from the baseline period efficacy will be evaluated at the end of the 24-week treatment period Safety assessments will be conducted throughout the trial The safety evaluation will be performed according to the Common Terminology Criteria for Adverse Events CTCAE version 50 by the National Cancer Institute
Study Population Patients with cirrhotic portal hypertension
Intervention Compound Alverine Citrate Capsules Lejiansu each capsule contains 60 mg of Alverine Citrate and 300 mg of Simethicone manufactured by the French company UCB Pharma 180 mgday 1 capsule orally 3 times a day taken continuously for 24 weeks
Study Objectives To evaluate the safety and efficacy of Compound Alverine Citrate Capsules in treating portal hypertension in patients with cirrhosis
Study Endpoints Primary Endpoints
1 Safety Assessment Incidence of adverse events serious adverse events and adverse events leading to discontinuation of treatment evaluated according to CTCAE version 50
2 Efficacy Assessment The response rate at 24 weeks of treatment defined as a reduction in HVPG by 10 from baseline or a reduction to below 12 mmHg
Secondary Endpoints
1 HVPG Changes The absolute value and percentage change in HVPG from baseline after 24 weeks of treatment
2 Decompensation Events Incidence of cirrhosis decompensation events during treatment including esophagealgastric variceal bleeding and re-bleeding new or worsening ascites spontaneous bacterial peritonitis overt hepatic encephalopathy and acute kidney injuryhepatorenal syndrome
3 12-Week Response Rate The treatment response rate at 12 weeks
4 Mortality and Transplantation Rates of death liver transplantation and liver disease-related mortality during the treatment period
Exploratory Endpoints
1 Cardiac Function Changes in cardiac function from baseline after 24 weeks of treatment
2 Liver and Spleen Stiffness Changes in liver and spleen stiffness from baseline after 24 weeks of treatment
3 Esophageal Varices Status of esophageal varices after 24 weeks of treatment
Sample Size Calculation This trial is a single-arm exploratory clinical study and plans to enroll 30 subjects
Study Population Patients with cirrhotic portal hypertension
Intervention Compound Alverine Citrate Capsules Lejiansu each capsule contains 60 mg of Alverine Citrate and 300 mg of Simethicone manufactured by the French company UCB Pharma 180 mgday 1 capsule orally 3 times a day taken continuously for 24 weeks
Study Objectives To evaluate the safety and efficacy of Compound Alverine Citrate Capsules in treating portal hypertension in patients with cirrhosis
Study Endpoints Primary Endpoints
1 Safety Assessment Incidence of adverse events serious adverse events and adverse events leading to discontinuation of treatment evaluated according to CTCAE version 50
2 Efficacy Assessment The response rate at 24 weeks of treatment defined as a reduction in HVPG by 10 from baseline or a reduction to below 12 mmHg
Secondary Endpoints
1 HVPG Changes The absolute value and percentage change in HVPG from baseline after 24 weeks of treatment
2 Decompensation Events Incidence of cirrhosis decompensation events during treatment including esophagealgastric variceal bleeding and re-bleeding new or worsening ascites spontaneous bacterial peritonitis overt hepatic encephalopathy and acute kidney injuryhepatorenal syndrome
3 12-Week Response Rate The treatment response rate at 12 weeks
4 Mortality and Transplantation Rates of death liver transplantation and liver disease-related mortality during the treatment period
Exploratory Endpoints
1 Cardiac Function Changes in cardiac function from baseline after 24 weeks of treatment
2 Liver and Spleen Stiffness Changes in liver and spleen stiffness from baseline after 24 weeks of treatment
3 Esophageal Varices Status of esophageal varices after 24 weeks of treatment
Sample Size Calculation This trial is a single-arm exploratory clinical study and plans to enroll 30 subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None